MYRIAD GENETICS INC 10-K

Item 9A. CONTROLS AND PROCEDURES 1. Disclosure Controls and Procedures We maintain disclosure controls and procedures (Disclosure Controls) within the meaning of Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Annual Report on Form 10-K, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily applied its judgment in evaluating and implementing possible controls and procedures. As of the end of the period covered by this Annual Report on Form 10-K, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2023, our Disclosure Controls were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. 2. Management’s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a‑15(f) and 15d‑15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States. Our management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2023, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013). We have evaluated the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual Report on Form 10-K, with the participation of our Chief Executive Officer and Chief Financial Officer, as well as other key members of our management. Based on this assessment, management concluded that, as of December 31, 2023, the Company's internal control over financial reporting was effective. The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report included elsewhere herein. 3. Change in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting that occurred during the quarter or year ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 107 Table of Contents 4. Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Myriad Genetics, Inc. Opinion on Internal Control Over Financial Reporting We have audited Myriad Genetics, Inc. and subsidiaries’ internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Myriad Genetics, Inc. and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and our report dated February 28, 2024 expressed an unqualified opinion thereon. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control Over Financial Reporting A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ Ernst & Young LLP Salt Lake City, UT February 28, 2024 108 Table of Contents Item 9B. OTHER INFORMATION (b) Rule 10b5-1 Trading Plans On November 22, 2023 , Dan Spiegelman , a member of the Company's Board of Directors , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale in multiple transactions of 50% of the shares to be acquired upon the vesting of Mr. Spiegelman's award of 15,151 restricted stock units granted on June 1, 2023. The plan expires on the earlier of (i) the date all of the shares under the plan have been sold and (ii) November 14, 2024. Except as disclosed above, none of our directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as such term is defined in Item 408(a) of Regulation S-K. Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS Not applicable . 109 Table of Contents PART III Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Management and Corporate Governance,” “Corporate Code of Conduct” and "Insider Trading Policies" in our Proxy Statement for the 2024 Annual Meeting of Stockholders expected to be held on June 6, 2024. Item 11. EXECUTIVE COMPENSATION The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Compensation Discussion and Analysis,” "Pay Versus Performance," “Management and Corporate Governance – Committees of the Board of Directors and Meetings – Compensation and Human Capital Committee Interlocks and Insider Participation,” “Compensation and Human Capital Committee Report ” and “Management and Corporate Governance – Board’s Role in the Oversight of Risk Management” in our Proxy Statement for the 2024 Annual Meeting of Stockholders expected to be held on June 6, 2024. Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Compensation Discussion and Analysis - Equity Compensation Plan Information” in our Proxy Statement for the 2024 Annual Meeting of Stockholders expected to be held on June 6, 2024. Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE The response to this item is incorporated by reference from the discussion responsive thereto under the caption “Certain Relationships and Related Person Transactions” and “Management and Corporate Governance – Director Independence” in our Proxy Statement for the 2024 Annual Meeting of Stockholders expected to be held on June 6, 2024. Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES The response to this item is incorporated by reference from the discussion responsive thereto in the proposal entitled “Selection of Independent Registered Public Accounting Firm” in our Proxy Statement for the 2024 Annual Meeting of the Stockholders expected to be held on June 6, 2024. 110 Table of Contents PART IV Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a) The following documents are included as part of this Annual Report on Form 10-K. 1. Financial Statements See “Index to Consolidated Financial Statements” under Part II, Item 8 to this Annual Report on Form 10-K. 2. Financial Statement Schedules Financial statement schedules have not been included because they are not applicable, or the information is included in financial statements or notes thereto. 3. Exhibits Exhibit Number Exhibit Description Filed with this Report Incorporated by Reference herein from Form or Schedule Filing Date SEC File/ Registration Number 3.1 Restated Certificate of Incorporation, as amended 10-Q (Exhibit 3.1) 8/4/2023 000-26642 3.2 Restated By-Laws 8-K (Exhibit 3.1) 10/15/2020 000-26642 4.1 Specimen Common Stock Certificate 10-K (Exhibit 4.1) 8/15/2011 000-26642 4.2 Description of Securities 10-KT (Exhibit 4.2) 3/16/2021 000-26642 Lease Agreements 10.1 .1 Lease Agreement, dated October 12, 1995, between the Registrant and Boyer Research Park Associates V, by its general partner, the Boyer Company 10-Q (Exhibit 10.2) 11/8/1996 000-26642 .2 Amendment to Phase I Lease Agreement, dated February 3, 2016, between the Registrant and HCPI/UTAH II, LLC. 10-Q (Exhibit 10.1) 5/4/2016 000-26642 .3 L ease Termination Agreement, dated December 18, 2023, between the R e gistrant and HCPI/Utah II, LLC X 10.2 .1 Lease Agreement-Research Park Building Phase II, dated March 6, 1998, between the Registrant and Research Park Associated VI, by its general partner, the Boyer Company, L.C. 10-K (Exhibit 10.44) 9/24/1998 000-26642 .2 Amendment to Phase II Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc. and HCPI/UTAH II, LLC . 10-Q (Exhibit 10.2) 5/4/2016 000-26642 .3 L ease Termination Agreement, dated December 18, 2023, between Myriad Genetics, Inc. and HCPI/Utah II, LLC. X 10.3 .1 Lease Agreement, dated March 31, 2001, between the Registrant and Boyer Research Park Associates VI, by its general partner, The Boyer Company, L.C. 10-Q (Exhibit 10.1) 5/15/2001 000-26642 .2 Amendment to Phase III Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc. and HCPI/UTAH II, LLC. 10-Q (Exhibit 10.3) 5/4/2016 000-26642 111 Table of Contents Exhibit Number Exhibit Description Filed with this Report Incorporated by Reference herein from Form or Schedule Filing Date SEC File/ Registration Number .3 Lease Termination Agreement, dated December 18, 2023, between Myriad Genetics, Inc. and HCPI/Utah II, LLC X 10.4 L ease Agreement, dated February 9, 2022, between Myriad Genetics, Inc. and Bay Bridge/Corporate, LLC. X 10.5 L ease, effective December 7, 2021, b etween Myriad Women's Health, Inc. and Bayside Area Development, LLC. X Agreements with Executive Officers and Directors 10.6 Non-Employee Director Compensation Policy (effective June 2023)+ 10-Q (Exhibit 10.4) 8/4/2023 000-26642 10.7 Form of director and executive officer indemnification agreement+ 10-K (Exhibit 10.34) 8/25/2009 000-26642 10.8 Form of Severance and Change in Control Agreement+ 8-K (Exhibit 10.1) 10/15/2020 000-26642 10.9 Executive Employment Agreement between the Registrant and Paul J. Diaz dated July 24, 2020+ 10-Q (Exhibit 10.1) 11/9/2020 000-26642 10.10 Performance-Based Restricted Stock Unit Agreement between Registrant and Paul J. Diaz dated October 8, 2020+ 10-Q (Exhibit 10.2) 11/9/2020 000-26642 10.11 Restricted Stock Unit Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ 10-Q (Exhibit 10.3) 11/9/2020 000-26642 10.12 Performance-Based Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ 10-Q (Exhibit 10.4) 11/9/2020 000-26642 10.13 Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ 10-Q (Exhibit 10.5) 11/9/2020 000-26642 10.14 Form of Separation and Release Agreement between the Registrant and Paul J. Diaz+ 10-Q (Exhibit 10.6) 11/9/2020 000-26642 10.15 Executive Employment Agreement, dated October 17, 2023 , between Myriad Genetics, Inc. and Samraat S. Raha + 10-Q (Exhibit 10.2) 11/7/2023 000-26642 10.16 Severance and Change of Control Agreement, dated December 11, 2023, by and between Myriad Genetics, Inc. and Samraat S. Raha+ X 10.17 E xecutive Employment Agreement, dated December 15, 2023, between Myriad Genetics, Inc. and Scott Leffler + X 10.18 Sepa ration and Consulting Agreement and Release of Claims, dated December 15, 2023 , between Myriad Genetics, Inc. and R. Bryan Riggsbee + X 112 Table of Contents Exhibit Number Exhibit Description Filed with this Report Incorporated by Reference herein from Form or Schedule Filing Date SEC File/ Registration Number 10.19 Separation and Consulting Agreement and Release of Claims, dated October 4, 2023, by and between Myriad Genetics, Inc. and Nicole Lambert + X Equity Compensation Plans 10.20 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (June 1, 2023)+ 8-K (Exhibit 10.1+) 6/2/2023 000-26642 10.21 Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan+ 10-K (Exhibit 10.11) 8/13/2020 000-26642 10.22 Amended and Restated 2012 Employee Stock Purchase Plan + 8-K (Exhibit 10.1) 6/2/2022 000-26642 10.23 Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan (Employee) + 10-Q (Exhibit 10.1) 5/4/2023 000-26642 10.24 2013 Executive Incentive Plan, as amended+ 8-K (Exhibit 10.2) 12/1/2017 000-26642 Credit Agreement 10.25 Credit Agreement dated June 30, 2023, among Myriad Genetics, Inc., the other loan parties from time to time party thereto, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent and issuing bank. 8-K (Exhibit 10.1) 7/6/2023 000-26642 10.26 Pledge and Security Agreement dated June 30, 2023, among Myriad Genetics, Inc., each of the other Guarantors and JPMorgan Chase Bank, N.A., as administrative agent for the secured parties. 8-K (Exhibit 10.2) 7/6/2023 000-26642 10.27 First Amendment to Credit Agreement and Pledge and Security Agreement, dated as of October 31, 2023, among Myriad Genetics, Inc., the other loan parties party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent. 8-K (Exhibit 10.1) 10/31/2023 000-26642 Other Exhibits 21.1 List of Subsidiaries of the Registrant X 23.1 Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP) X 24.1 Power of Attorney (included in the signature page hereto) X 113 Table of Contents Exhibit Number Exhibit Description Filed with this Report Incorporated by Reference herein from Form or Schedule Filing Date SEC File/ Registration Number 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 X 97.1 C lawback Policy X 101 The following materials from Myriad Genetics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements. Inline XBRL Instance Document – Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. X 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) X (+) Management contract or compensatory plan arrangement. Item 16. FORM 10-K SUMMARY None. 114 Table of Contents SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 28, 2024 . MYRIAD GENETICS, INC. By: /s/ Paul J. Diaz Paul J. Diaz President and Chief Executive Officer Power of Attorney KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Paul J. Diaz and Scott J. Leffler and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below and on the dates indicated. 115 Table of Contents Signatures Title Date President, Chief Executive Officer and Director (Principal Executive Officer) By: /s/ Paul J. Diaz February 28, 2024 Paul J. Diaz Chief Financial Officer (Principal Financial Officer) By: /s/ Scott J. Leffler February 28, 2024 Scott J. Leffler Chief Accounting Officer (Principal Accounting Officer) By: /s/ Natalie Munk February 28, 2024 Natalie Munk By: /s/ S. Louise Phanstiel Chair of the Board February 28, 2024 S. Louise Phanstiel By: /s/ Paul Bisaro Director February 28, 2024 Paul Bisaro By: /s/ Heiner Dreismann Director February 28, 2024 Heiner Dreismann, Ph.D. By: /s/ Rashmi Kumar Director February 28, 2024 Rashmi Kumar By: /s/ Lee N. Newcomer Director February 28, 2024 Lee N. Newcomer, M.D. By: /s/ Colleen F. Reitan Director February 28, 2024 Colleen F. Reitan By: /s/ Daniel M. Skovronsky Director February 28, 2024 Daniel M. Skovronsky, M.D., Ph.D. By: /s/ Daniel K. Spiegelman Director February 28, 2024 Daniel K. Spiegelman 116